Stage III Non-Small Cell Lung Cancer

Publication Date: July 19, 2023
Last Updated: July 20, 2023


Evaluation and Staging

Recommendation 1.1

For patients with suspected stage III NSCLC, an evaluation to exclude metastatic disease should include, at a minimum: history and physical exam and computed tomography (CT) scan of chest and upper abdomen (with contrast, unless contraindicated). (IC, B, L, S)
Clinical interpretation: Any suspected metastatic site identified on CT should be confirmed pathologically with biopsy. In general, biopsy sites should be selected to confirm highest possible disease stage, and to maximize tissue yield.



Recommendation 2.1
For patients with stage IIIA (N2) NSCLC, induction therapy followed by surgery (with or without adjuvant therapy) may be offered if all of the following conditions are met:
  1. A complete resection (R0) of the primary tumor and involved lymph nodes is deemed possible.
  2. N3 lymph nodes are deemed to be not involved by multidisciplinary consensus.
  3. Perioperative (90-day) mortality is expected to be low (≤5%).
(EB, B, M, W)



Management of Stage III Non-Small Cell Lung Cancer

Authoring Organization